265 related articles for article (PubMed ID: 37327022)
1. Emerging Role of Sphingolipids in Amphotericin B Drug Resistance.
Madaan K; Bari VK
Microb Drug Resist; 2023 Aug; 29(8):319-332. PubMed ID: 37327022
[TBL] [Abstract][Full Text] [Related]
2. Antifungal drug resistance in Candida: a special emphasis on amphotericin B.
Ahmady L; Gothwal M; Mukkoli MM; Bari VK
APMIS; 2024 May; 132(5):291-316. PubMed ID: 38465406
[TBL] [Abstract][Full Text] [Related]
3. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
4. The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.
Mesa-Arango AC; Trevijano-Contador N; Román E; Sánchez-Fresneda R; Casas C; Herrero E; Argüelles JC; Pla J; Cuenca-Estrella M; Zaragoza O
Antimicrob Agents Chemother; 2014 Nov; 58(11):6627-38. PubMed ID: 25155595
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence studies on the molecular action of amphotericin B on susceptible and resistant fungal cells.
Haynes MP; Chong PL; Buckley HR; Pieringer RA
Biochemistry; 1996 Jun; 35(24):7983-92. PubMed ID: 8672502
[TBL] [Abstract][Full Text] [Related]
6. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
[TBL] [Abstract][Full Text] [Related]
7. Unmasking the Amphotericin B Resistance Mechanisms in
Silva LN; Oliveira SSC; Magalhães LB; Andrade Neto VV; Torres-Santos EC; Carvalho MDC; Pereira MD; Branquinha MH; Santos ALS
ACS Infect Dis; 2020 May; 6(5):1273-1282. PubMed ID: 32239912
[TBL] [Abstract][Full Text] [Related]
8. Artemisinin elevates ergosterol levels of Candida albicans to synergise with amphotericin B against oral candidiasis.
Zhu C; Liao B; Ye X; Zhou Y; Chen X; Liao M; Cheng L; Zhou X; Ren B
Int J Antimicrob Agents; 2021 Sep; 58(3):106394. PubMed ID: 34197906
[TBL] [Abstract][Full Text] [Related]
9. Dectin-1-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy.
Ambati S; Ferarro AR; Kang SE; Lin J; Lin X; Momany M; Lewis ZA; Meagher RB
mSphere; 2019 Feb; 4(1):. PubMed ID: 30760610
[No Abstract] [Full Text] [Related]
10. Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy.
Ambati S; Ellis EC; Lin J; Lin X; Lewis ZA; Meagher RB
mSphere; 2019 Oct; 4(5):. PubMed ID: 31666315
[No Abstract] [Full Text] [Related]
11. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
12. [Neonatal Candida infections and the antifungal susceptibilities of the related Candida species].
Altuncu E; Bilgen H; Cerikçioğlu N; Ilki A; Ulger N; Bakır M; Akman I; Ozek E
Mikrobiyol Bul; 2010 Oct; 44(4):593-603. PubMed ID: 21063972
[TBL] [Abstract][Full Text] [Related]
13. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
14. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.
Yang H; Chaudhari P; Zhou ZY; Wu EQ; Patel C; Horn DL
Appl Health Econ Health Policy; 2014 Feb; 12(1):85-93. PubMed ID: 24385260
[TBL] [Abstract][Full Text] [Related]
15. Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles.
Vazquez JA; Arganoza MT; Boikov D; Yoon S; Sobel JD; Akins RA
J Clin Microbiol; 1998 Sep; 36(9):2690-5. PubMed ID: 9705415
[TBL] [Abstract][Full Text] [Related]
16. Comparative Transcriptomics Reveal Possible Mechanisms of Amphotericin B Resistance in Candida auris.
Shivarathri R; Jenull S; Chauhan M; Singh A; Mazumdar R; Chowdhary A; Kuchler K; Chauhan N
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0227621. PubMed ID: 35652307
[TBL] [Abstract][Full Text] [Related]
17. Plasma Membrane Proteolipid 3 Protein Modulates Amphotericin B Resistance through Sphingolipid Biosynthetic Pathway.
Bari VK; Sharma S; Alfatah M; Mondal AK; Ganesan K
Sci Rep; 2015 May; 5():9685. PubMed ID: 25965669
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B-silver hybrid nanoparticles: synthesis, properties and antifungal activity.
Tutaj K; Szlazak R; Szalapata K; Starzyk J; Luchowski R; Grudzinski W; Osinska-Jaroszuk M; Jarosz-Wilkolazka A; Szuster-Ciesielska A; Gruszecki WI
Nanomedicine; 2016 May; 12(4):1095-1103. PubMed ID: 26772425
[TBL] [Abstract][Full Text] [Related]
19. The vacuole-targeting fungicidal activity of amphotericin B against the pathogenic fungus Candida albicans and its enhancement by allicin.
Borjihan H; Ogita A; Fujita K; Hirasawa E; Tanaka T
J Antibiot (Tokyo); 2009 Dec; 62(12):691-7. PubMed ID: 19876074
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
